Paul S Wissel MD
Gastrointestinal Cancer, Hematologic Oncology
Clinical Professor--University of Pennsylvania
Join to view full profile
3400 Civic Center BlvdPhiladelphia, PA 19104
Phone+1 215-615-5858
Fax+1 215-349-8144
Dr. Wissel is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Rockefeller University HospitalFellowship, Drug Metabolism and Pharmacology, 1985 - 1987
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1982 - 1985
University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 1981 - 1982
Ohio State University HospitalResidency, Internal Medicine, 1979 - 1981
Columbia University Vagelos College of Physicians and SurgeonsClass of 1979
Certifications & Licensure
PA State Medical License 1989 - 2026
NC State Medical License 1992 - 2017
OH State Medical License 1980 - 1984
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
National Board of Physicians and Surgeons Internal Medicine- National Board of Physicians and Surgeons Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
Publications & Presentations
PubMed
- 11 citationsCirculating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma.Jacob E Till, Lee McDaniel, Changgee Chang, Qi Long, Shannon M Pfeiffer
Nature Communications. 2024-07-09 - A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer.Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, Enriqueta Felip, Suresh S Ramalingam
Future Oncology. 2024-01-01 - 52 citationsPhase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With-Mutant Metastatic Non-Small-Cell Lung Cancer.Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, Enriqueta Felip, Suresh S Ramalingam
Journal of Clinical Oncology. 2023-07-20
Grant Support
- Diet-induced modification of sweet taste perception and preference: A potential strategy to aid in population-wide reduction in sugar intakeMONELL CHEMICAL SENSES CENTER2018–2025
- Diet-induced modification of sweet taste perception and preference: A potential strategy to aid in population-wide reduction in sugar intakeMONELL CHEMICAL SENSES CENTER2018–2025
- Diet-induced modification of sweet taste perception and preference: A potential strategy to aid in population-wide reduction in sugar intakeMONELL CHEMICAL SENSES CENTER2018–2025
- Endocrinology/CancerNational Center For Research Resources1985–1986
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
